论文部分内容阅读
目的：评价紫杉醇联合卡培他滨治疗进展期胃癌的临床疗效和安全性。方法用紫杉醇联合卡培他滨方案治疗进展期胃癌患者36例。方案为紫杉醇175mg/m2,静脉滴注3h,第l天；希罗达1250mg/m2,每天2次,第1～14天,21天为1个周期,连用2个周期后评价疗效。结果36例中,获得完全缓解(CR)4例,占11.1%；部分缓解(PR)15例,占41.7%；稳定(SD)12例,占33.3%；进展(PD)5例,占13.9%。总有效率(CR+PR)为52.8%。中位疾病进展时间(TTP)为7.98个月(95%CI为4.36～8.53)；中位生存期时间(OS)为9.06个月(95%CI为4.56～14.18)，1年生存率为56.45%。不良反应主要为恶心呕吐、骨髓抑制、腹泻、手足综合征、脱发、中性粒细胞减少等,未出现治疗相关性死亡。结论紫杉醇联合卡培他滨治疗进展期胃癌患者临床疗效较高,不良反应轻而且安全。“,”Objective:We evaluated the antitumour activity and toxicities of paclitaxel and xeloda as therapy in patientswith advanced gastric cancer(AGC).M Ethods:Patientswith histological y confirmed unresectable ormetastaticAGC were treated with xeloda 1 000mg/m2 p. o. twice daily on days 1-14 and paclitaxel 175mg/m2.i v. on day 1 every 3 weeks until disease progression or unacceptable toxicities. Results: A total of 4 patients showed complete response and 15 showed partial response making the overal response rate 52.8%. Median time to progression was 7.98 months (95%CI4.36~8.53) and median overal survival time was 9.06 months (95%CI 4.56~14.18). Grade 3 or 4 adverse events include leukocytopenia, diarrhea, hand-foot syndrome, CINV, and alopecia. There was no leukocytopenia feveror treatment-related deaths.Conclusion: Paclitaxel and xeloda combination chemotherapy was active and highly tolerable as a therapy for AGC.